Generex Biotechnology Announces Extension to the Pay Date for the Previously Declared 1:1 Stock Dividend

NEXT STORY
CrownBio und NEXT Oncology geben strategische PDX-Modellpartnerschaft bekannt
PREV STORY
The global biopsy devices market was valued at $2,728 million in 2018 and is expected to reach $4,310 million by 2026
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Generex Biotechnology Announces Extension to the Pay Date for the Previously Declared 1:1 Stock Dividend

NEXT STORY
CrownBio und NEXT Oncology geben strategische PDX-Modellpartnerschaft bekannt
PREV STORY
The global biopsy devices market was valued at $2,728 million in 2018 and is expected to reach $4,310 million by 2026
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

author_avatar
NASDAQ Market News

Cellectar Biosciences To Present at the 18th Annual Rodman & Renshaw Global Investment Conference

MADISON, Wis., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), ...

author_avatar
NASDAQ Market News

Inozyme Pharma Appoints Deborah Wenkert, M.D., as Senior Vice President and Chief Medical Officer

author_avatar
NASDAQ Market News